异动解读|三倍做多标普生物-Direxion盘中上涨5.63%,生物医药审批与研发进展提振板块

行情直击
Nov 19

11月19日,三倍做多标普生物-Direxion盘中上涨5.63%,报201.605美元,成交额4729.17万美元。

消息面上,生物医药板块当日迎来多项监管与研发进展,带动做多型杠杆ETF走强。其中,再生元与Alnylam联合开发的gMG疗法Livsayis获FDA批准,成为首个获批治疗gMG的siRNA疗法;同时,GE Healthcare宣布其锰基MRI对比剂mangaciclanol在2/3期试验的2期阶段达到主要终点,支持推进3期研究。

此外,阿斯利康胃癌药sonesitatug vedotin获FDA优先审评,Hutchmed的sovleplenib获孤儿药资格,行业内密集利好强化了市场对生物科技与创新药资产的风险偏好。

(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10